Bellevue Group’s Denali Therapeutics DNLI Stock Holding History

Bellevue Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$457K	Hold	17,766	–	–	0.01%	112
2026 Q1	$341K	Buy	17,766 +10,628	+149%	+$211K	0.01%	119
2025 Q4	$118K	Buy	+7,138	New	+$120K	﹤0.01%	159
2025 Q1	–	Sell	-15,700	Closed	-$320K	–	154
2024 Q4	$320K	Hold	15,700	–	–	0.01%	135
2024 Q3	$457K	Buy	+15,700	New	+$389K	0.01%	131
2023 Q3	–	Sell	-44,050	Closed	-$1.3M	–	158
2023 Q2	$1.3M	Buy	44,050 +13,050	+42%	+$367K	0.02%	120
2023 Q1	$714K	Hold	31,000	–	–	0.01%	136
2022 Q4	$862K	Hold	31,000	–	–	0.01%	139
2022 Q3	$951K	Buy	+31,000	New	+$1.01M	0.01%	137

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bellevue Group's DNLI Position: Q2 2026 in Review

Bellevue Group held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 17,766 shares worth $457K. The position accounts for 0.01% of the portfolio, ranked #112.

Bellevue Group first reported a position in DNLI in Q3 2022 and has held it in 9 quarters since. The position peaked at $1.3M in Q2 2023. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Bellevue Group held 17,766 shares of Denali Therapeutics worth $457K as of Q2 2026.
Bellevue Group left its Denali Therapeutics share count unchanged in Q2 2026.
Denali Therapeutics made up 0.01% of Bellevue Group's portfolio in Q2 2026, its #112 holding.
Bellevue Group first reported a position in Denali Therapeutics in Q3 2022 and has held it in 9 quarters since.
Bellevue Group's Denali Therapeutics position peaked at $1.3M in Q2 2023.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.